Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICON-1 + aflibercept
- Development stage
- Discontinued
- Lead developer
- Iconic Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
ICON-1 + aflibercept is an investigational combination therapy for neovascular (wet) age-related macular degeneration (AMD), composed of ICON-1, an anti-Tissue Factor (TF) fusion protein, and aflibercept, a recombinant fusion protein acting as a decoy receptor for vascular endothelial growth factor (VEGF). ICON-1 specifically targets pathologic vessels overexpressing TF, inhibiting abnormal choroidal neovascularization (CNV) and exudation, while aflibercept blocks VEGF-driven angiogenesis by binding VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing their interaction with endogenous receptors. The combination aims for synergistic disease modification, improved visual acuity, and more durable outcomes by acting on different mechanisms related to neovascularization and fluid exudation[3][5].
- Other names
- ICON-1 + afliberceptICON-1 and afliberceptICON1 and afliberceptICON 1 and afliberceptICON-1 with afliberceptICON1 with afliberceptICON 1 with aflibercept
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on ICON-1 + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICON-1 + aflibercept.